
Kenya: Mwalimu sacco foregoes $62mln put in Spire Bank
Mwalimu Deposit taking National Sacco has received regulatory approval to write off Ksh8 billion ($62.01 million) of bungled investments in the collapsed Spire Bank. It is a sacrifice necessary to turn around its fortunes that have seen the Sacco facing total collapse.
Now regulators want it to also reorganise its insurance and asset management business into separate, independent units to prevent further financial bleeding.
The sacco owned by teachers is working to regain a solid financial footing after investing over Ksh13 billion ($100.77 million) of members savings into a troubled third tier lender that collapsed after a string of losses. The Central Bank of Kenya has now granted conditional approval for its eventual liquidation.
Mwalimu Sacco had been Kenya's largest by assets (Ksh66.43 billion, $514.96 million). But it has now agreed on a six-year (2022-2027) capital deficiency restoration plan to gradually cancel and remove the Ksh8 billion ($62.01 million) failed investment from its books. It is a move aimed at preventing drastic depletion of reserves and ensuring the society continues to operate as normal.'In 2014, of course, we had some investments that did not go down well. Actually, it slowed down our growth projections we were looking at such as revenues, total assets among other parameters,' Kenneth Odhiambo, CEO of Mwalimu Sacco told The EastAfrican in an interview this week.'So, it slowed us down a little bit until 2022 when we offloaded the bank that we had bought, of course, which did not do well and now we picked up from there and changed our business model in terms of how were to operate.'After that, he says the sacco approached the Central Bank to discuss an arrangement on capital restoration.'We agreed that can we write off these losses over a period of time without interfering with the business. It would be almost Ksh8 billion ($62.01 million), and we agreed on a time frame of around six years.'The plan has been approved by the Sacco Societies Regulatory Authority (SASRA) in consultation with the Ministry of Co-operatives. It allows Mwalimu sacco management to write off the investments gradually.
So far, the sacco has written off Ksh2.49 billion ($19.3 million) in three years comprising Ksh700 million ($5.42 million) in 2022, Ksh846 million ($6.55 million) in 2023 and Ksh948 million ($7.34 million) in 2024, with plans scale up the monthly write offs to Ksh1.7 billion ($13.17 million) in 2026 and eventually clear the whole amount in 2027.
Mr Odhiambo says the sacco has changed its operating model to improve revenue and keep the business afloat. It is targeting to raise revenues from Ksh9.3 billion ($72.09 million) in 2024 to Ksh13.1 billion ($101.55 million) in 2025.
One way of achieving that, he said, is to recruit more members from among the teaching community, extending its presence to the grassroots, green financing and transactions incomes from the digital platforms.
The sacco has also procured the services of consultancy and audit firm Ernst&Young (E&Y) to restructure its insurance and asset management business by June this year to de-link its core (Sacco) business from the non-core business.
The Sacco runs two main subsidiaries —Mwalimu Risk Insurance Brokers and Mwalimu asset management.'One thing we have also done is that we will restructure our other subsidiaries, something that has gotten regulatory approval. We want to disengage them totally from the Sacco business so that they can operate separately and get their own funds to be able to operate.'Insurance brokerage and asset management,' said Odhiambo.'By June we shall be doing the transactions to restructure our group and ensure that the performances of those subsidiaries does not affect the main Sacco.'Mwalimu Sacco had acquired 100 percent shareholding in Spire bank (formerly Equatorial Commercial Bank) from the then late business tycoon Naushad Merali in a deal estimated at Ksh3 billion ($23.25 million) between 2015 and 2020Mwalimu Sacco first acquired 75 percent shareholding from Mr Merali at a price of Ksh2.4 billion ($18.6 million) 2015 and later acquired the remaining 25 percent in November 2020.
However, Spire Bank fell into a financial crisis soon after. The Sacco's board would blame Merali for the poor performance of the Bank after he withdrew all of his deposits amounting to Ksh1.7 billion ($13.17 million) in 2016 immediately after selling his shares.
In September 2022, Equity bank announced it had entered into an agreement to acquire Ksh945 million ($7.32 million) worth of loans and another Ksh1.32 billion ($10.23 million worth of deposits from the struggling lender.
That deal would be concluded in February 2023 and Equity Bank acquired about 20,000 new depositors and 3,700 new loan customers from Spire bank.
Currently the lender is awaiting a liquidator's hammer, though, in a move that would fold it up completely.'The bank is with CBK, and we have even done a declaration for it to be dissolved. It is no longer even having any impact on us actually.'That is why we are even waiting for the CBK to give us a nod so that we can get a liquidator to come and liquidate the assets as well. The beauty of it is that most of the depositors had gone and loans also have gone,' said Odhiambo.
© Copyright 2022 Nation Media Group. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116869007-14991234.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C676%2Cx0%2Cy73%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fusatoday.com.png&w=48&q=75)
USA Today
26 minutes ago
- USA Today
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview Carson Branstine (No. 231 ranking) will take on Elena-Gabriela Ruse (No. 80) in the Round of 16 of the Libema Open on Thursday, June 12. Ruse is the favorite against Branstine for this match, with -275 odds against the the underdog's +270. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Carson Branstine vs. Elena-Gabriela Ruse matchup info Tournament: Libema Open Libema Open Round: Round of 16 Round of 16 Date: Thursday, June 12 Thursday, June 12 Court Surface: Grass Watch the Tennis Channel and more sports on Fubo! Branstine vs. Ruse Prediction Based on the implied probility from the moneyline, Branstine has a 73.3% to win. Branstine vs. Ruse Betting Odds Branstine vs. Ruse matchup performance & stats


CNBC
26 minutes ago
- CNBC
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.
Yahoo
26 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data